Table 3.
Multivariate logistic analyses to identify predictors of PHLF in patients with HCC
| Characteristics | Child–Pugh score*
|
MELD score**
|
ALBI score‡
|
APRI score‡‡
|
||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
|
| ||||||||
| Male sex | 0.352 (0.193–0.642) | 0.001 | 0.409 (0.219–0.762) | 0.005 | 0.369 (0.199–0.684) | 0.002 | 0.388 (0.205–0.732) | 0.003 |
| HBV DNA | 1.445 (1.025–2.038) | 0.036 | 1.468 (1.040–2.071) | 0.029 | 1.502 (1.068–2.112) | 0.019 | 1.462 (1.021–2.093) | 0.038 |
| >2,000 IU/mL | ||||||||
| Plt count (109/L) | 0.991 (0.989–0.994) | <0.001 | 0.992 (0.990–0.995) | <0.001 | 0.992 (0.990–0.995) | <0.001 | ||
| TBil (μmol/L) | 1.068 (1.042–1.096) | <0.001 | ||||||
| PA (mg/L) | 0.994 (0.992–0.998) | <0.001 | 0.995 (0.992–0.998) | <0.001 | 0.997(0.994–0.999) | 0.016 | 0.996 (0.993–0.999) | 0.004 |
| ALB (g/L) | 1.008 (1.004–1.012) | 0.532 | 0.959 (0.923–0.997) | 0.035 | ||||
| ALT (U/L) | 1.002 (0.997–1.007) | 0.427 | 1.001 (0.996–1.007) | 0.592 | 1.002 (0.997–1.007) | 0.451 | 0.999 (0.994–1.004) | 0.730 |
| AST (U/L) | 1.009 (1.005–1.014) | <0.001 | 1.009 (1.005–1.013) | <0.001 | 1.009 (1.005–1.013) | <0.001 | ||
| Cre (μmol/L) | 0.998 (0.991–1.006) | 0.635 | 1.001 (0.993–1.007) | 0.929 | 0.999 (0.992–1.006) | 0.768 | ||
| PT (seconds) | 1.256 (1.083–1.457) | 0.003 | 1.266 (1.094–1.464) | 0.002 | 1.272 (1.101–1.471) | 0.001 | ||
| INR | 9.174 (2.311–36.42) | 0.002 | 18.95 (4.842–74.15) | <0.001 | ||||
| Ascites | 1.114 (0.648–1.916) | 0.695 | 1.104 (0.641–1.901) | 0.721 | 1.024 (0.590–1.775) | 0.934 | ||
| CSPH | 1.055 (0.590–1.886) | 0.856 | 0.994 (0.566–1.746) | 0.984 | 0.893 (0.491–1.624) | 0.711 | 0.852 (0.450–1.614) | 0.624 |
| Child–Pugh score | 1.524 (1.150–2.019) | 0.003 | ||||||
| MELD score | 1.060 (1.012–1.111) | 0.015 | ||||||
| ALBI score | 2.000 (1.204–3.321) | 0.007 | ||||||
| APRI score | 2.046 (1.542–2.714) | <0.001 | ||||||
| Cirrhosis | 1.600 (1.119–2.289) | 0.010 | 1.453 (1.009–2.092) | 0.044 | 1.461 (1.014–2.104) | 0.042 | 1.519 (1.066–2.166) | 0.021 |
| Tumor size (cm) | 1.050 (1.001–1.101) | 0.045 | 1.054 (1.004–1.106) | 0.032 | 1.055 (1.005–1.107) | 0.030 | 1.074 (1.034–1.114) | <0.001 |
| Multiple tumors, n | 1.816 (1.097–3.006) | 0.012 | 1.878 (1.127–3.128) | 0.015 | 1.853 (1.111–3.090) | 0.018 | 1.743 (1.048–2.898) | 0.032 |
| Blood loss ≥400 mL | 1.436 (1.003–2.057) | 0.048 | 1.462 (1.017–2.104) | 0.041 | 1.443 (1.001–2.081) | 0.049 | 1.498 (1.050–2.138) | 0.026 |
| Major resection | 1.900 (1.287–2.806) | 0.001 | 2.002 (1.345–2.978) | 0.001 | 2.006 (1.436–2.990) | 0.001 | 1.976 (1.365–2.858) | <0.001 |
Notes:
*
Without TBil, Alb, PT, INR, ascites, MELD, ALBI, and APRI scores.
**
Without TBil, INR, CRE, Child–Pugh, ALBI, and APRI scores.
‡
Without TBil, Alb, Child–Pugh, MELD, and APRI scores.
‡‡
Without AST, Plt count, Child–Pugh, MELD, and ALBI scores.
Abbreviations: Alb, albumin; ALBI, albumin–bilirubin; APRI, aspartate aminotransferase-to-platelet-ratio index; Cre, creatinine; CSPH, clinically significant portal hypertension; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; INR, international normalized ratio; MELD, model for end-stage liver disease; PA, prealbumin; Plt, platelet; PT, prothrombin time; TBil, total bilirubin.